Monopar Therapeutics News and Activities

Monopar Therapeutics is a company listed under the stock ticker MNPR (US).

View the org chart displaying its 13 main executives

Most searched biographies at Monopar Therapeutics

• Chandler Robinson, Chief Executive Officer and Board Membe
• Raymond Anderson, Director
• Christopher Starr, Executive Chairman of the Board

Popular executive movements at Monopar Therapeutics

• Susan Rodriguez has joined the company as Chief Commercial and Strategy Officer  (posted on May 19 2026).
• Susan Rodrigue has joined the company as Chief Commercial Officer  (posted on March 4 2026).

Create your alert
to follow the executive moves at Monopar Therapeutics.

Monopar Therapeutics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Monopar Therapeutics

• Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
• Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu
• Press Releases
• Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference
• Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
• Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock
• Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock
• Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock
• Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
• Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024
• View more press releases Close

Social media about Monopar Therapeutics

• Monopar Therapeutics on Wikipedia, Google News & Yahoo Finance
• Monopar Therapeutics on LinkedIn, X (Twitter) & YouTube